Back to Search Start Over

Hypofractionated Radiotherapy in Localized, Low-Intermediate-Risk Prostate Cancer: Current and Future Prospectives.

Authors :
Lo Greco MC
Marletta G
Marano G
Fazio A
Buffettino E
Iudica A
Liardo RLE
Milazzotto R
Foti PV
Palmucci S
Basile A
Marletta F
Cuccia F
Ferrera G
Parisi S
Pontoriero A
Pergolizzi S
Spatola C
Source :
Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2023 Jun 14; Vol. 59 (6). Date of Electronic Publication: 2023 Jun 14.
Publication Year :
2023

Abstract

At the time of diagnosis, the vast majority of prostate carcinoma patients have a clinically localized form of the disease, with most of them presenting with low- or intermediate-risk prostate cancer. In this setting, various curative-intent alternatives are available, including surgery, external beam radiotherapy and brachytherapy. Randomized clinical trials have demonstrated that moderate hypofractionated radiotherapy can be considered as a valid alternative strategy for localized prostate cancer. High-dose-rate brachytherapy can be administered according to different schedules. Proton beam radiotherapy represents a promising strategy, but further studies are needed to make it more affordable and accessible. At the moment, new technologies such as MRI-guided radiotherapy remain in early stages, but their potential abilities are very promising.

Details

Language :
English
ISSN :
1648-9144
Volume :
59
Issue :
6
Database :
MEDLINE
Journal :
Medicina (Kaunas, Lithuania)
Publication Type :
Academic Journal
Accession number :
37374348
Full Text :
https://doi.org/10.3390/medicina59061144